You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News on molecular markers used to guide cancer treatment, assess prognosis, or detect relapse.
Two new studies revealed the prevalence of pathogenic variants in breast cancer-related genes, while highlighting genes that may be most informative in the clinic.
A data safety monitoring committee said the trial, exploring the first-line activity of bintrafusp against Keytruda in PD-L1-high, advanced NSCLC, wouldn't meet its primary endpoint.
The test will be used in the trial to improve understanding of molecular resistance mechanisms to Pfizer's Lorviqua and other ALK inhibitors.
The EMA granted conditional approval based on the drug's ability to shrink tumors in 61 percent of patients in the Phase II DESTINY-Breast01 trial.
The agency approved the new indication based on data showing that the drug improved survival in patients compared to chemotherapy.
The agency approved the drug based on a study that showed an 88 percent response rate in young patients with ALK-positive anaplastic large cell lymphoma.
The company will put funds toward a Phase I clinical trial of CT-0508, a HER2-targeted CAR macrophage therapy, which recently began enrolling patients.
Although a record number of new precision oncology drugs came to market, the pandemic further exposed access gaps that the field is focused on mitigating.
Ikena will use the funding to advance its TEAD inhibitor into human trials and to pursue a preclinical program targeting KRAS signaling.
Opdivo plus chemotherapy extended survival for gastric cancer patients whose tumors expressed PD-L1 and in all comers in the Phase III CheckMate-649 trial.